Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diabetes increases the risk of serious adverse events after re-irradiation of the spine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antineoplastic treatment with crizotinib during pregnancy: a case report

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Incorporating NTCP into Randomized Trials of Proton Versus Photon Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND AND PURPOSE: Local recurrence is frequent in locally advanced NSCLC and is primarily located in FDG-avid parts of tumour and lymph nodes. Aiming at improving local control without increasing toxicity, we designed a multi-centre phase-III trial delivering inhomogeneous dose-escalation driven by FDG-avid volumes, while respecting normal tissue constraints and requiring no increase in mean lung dose. Dose-escalation driven by FDG-avid volumes, delivering mean doses of 95Gy (tumour) and 74Gy (lymph nodes), was pursued and compared to standard 66Gy/33F plans.

MATERIAL AND METHODS: Dose plans for the first thirty patients enroled were analysed. Standard and escalated plans were created for all patients, blinded to randomization, and compared for each patient in terms of the ability to escalate while protecting normal tissue.

RESULTS: The median dose-escalation in FDG-avid areas was 93.9Gy (tumour) and 73.0Gy (lymph nodes). Escalation drove the GTV and CTV to mean doses for the tumour of 87.5Gy (GTV-T) and 81.3Gy (CTV-T) in median. No significant differences in mean dose to lung and heart between standard and escalated were found, but small volumes of e.g. the bronchi received doses between 66 and 74Gy due to escalation.

CONCLUSIONS: FDG-driven inhomogeneous dose-escalation achieves large increment in tumour and lymph node dose, while delivering similar doses to normal tissue as homogenous standard plans.

OriginalsprogEngelsk
TidsskriftRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Vol/bind124
Udgave nummer2
Sider (fra-til)311-317
Antal sider7
ISSN0167-8140
DOI
StatusUdgivet - aug. 2017

ID: 52024934